BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of long-term tubular HIF-2α overexpression on progressive renal fibrosis in a chronic kidney disease model

  • Dal-Ah Kim (Ewha Medical Research Center, Ewha Womans University College of Medicine) ;
  • Mi-Ran Lee (Department of Biomedical Laboratory Science, Jungwon University) ;
  • Hyung Jung Oh (Ewha Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital) ;
  • Myong Kim (Department of Urology, Ewha Womans University Seoul Hospital) ;
  • Kyoung Hye Kong (Ewha Medical Research Center, Ewha Womans University College of Medicine)
  • Received : 2022.10.12
  • Accepted : 2022.11.21
  • Published : 2023.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Renal fibrosis is the final manifestation of chronic kidney disease (CKD) regardless of etiology. Hypoxia-inducible factor-2 alpha (HIF-2α) is an important regulator of chronic hypoxia, and the late-stage renal tubular HIF-2α activation exerts protective effects against renal fibrosis. However, its specific role in progressive renal fibrosis remains unclear. Here, we investigated the effects of the long-term tubular activation of HIF-2α on renal function and fibrosis, using in vivo and in vitro models of renal fibrosis. Progressive renal fibrosis was induced in renal tubular epithelial cells (TECs) of tetracycline-controlled HIF-2α transgenic (Tg) mice and wild-type (WT) controls through a 6-week adenine diet. Tg mice were maintained on doxycycline (DOX) for the diet period to induce Tg HIF-2α expression. Primary TECs isolated from Tg mice were treated with DOX (5 ㎍/ml), transforming growth factor-β1 (TGF-β1) (10 ng/ml), and a combination of both for 24, 48, and 72 hr. Blood was collected to analyze creatinine (Cr) and blood urea nitrogen (BUN) levels. Pathological changes in the kidney tissues were observed using hematoxylin and eosin, Masson's trichrome, and Sirius Red staining. Meanwhile, the expression of fibronectin, E-cadherin and α-smooth muscle actin (α-SMA) and the phosphorylation of p38 mitogen-activated protein kinase (MAPK) was observed using western blotting. Our data showed that serum Cr and BUN levels were significantly lower in Tg mice than in WT mice following the adenine diet. Moreover, the protein levels of fibronectin and E-cadherin and the phosphorylation of p38 MAPK were markedly reduced in the kidneys of adenine-fed Tg mice. These results were accompanied by attenuated fibrosis in Tg mice following adenine administration. Consistent with these findings, HIF-2α overexpression significantly decreased the expression of fibronectin in TECs, whereas an increase in α-SMA protein levels was observed after TGF-β1 stimulation for 72 hr. Taken together, these results indicate that long-term HIF-2α activation in CKD may inhibit the progression of renal fibrosis and improve renal function, suggesting that long-term renal HIF-2α activation may be used as a novel therapeutic strategy for the treatment of CKD.

Keywords

Acknowledgement

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2019R1I1A1A01054994 and 2019R1I1A1A01055061).

References

  1. Fine LG and Norman JT (2008) Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74, 867-872  https://doi.org/10.1038/ki.2008.350
  2. Tanaka S, Tanaka T and Nangaku M (2015) Hypoxia and dysregulated angiogenesis in kidney disease. Kidney Dis (Basel) 1, 80-89  https://doi.org/10.1159/000381515
  3. Liu M, Ning X, Li R et al (2017) Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med 21, 1248-1259  https://doi.org/10.1111/jcmm.13060
  4. Liu J, Wei Q, Guo C et al (2017) Hypoxia, HIF, and associated signaling networks in chronic kidney disease. Int J Mol Sci 18, 950 
  5. Haase VH (2006) Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291, F271-F281  https://doi.org/10.1152/ajprenal.00071.2006
  6. Tanaka T (2016) Expanding roles of the hypoxia-response network in chronic kidney disease. Clin Exp Nephrol 20, 835-844  https://doi.org/10.1007/s10157-016-1241-4
  7. Mimura I, Tanaka T and Nangaku M (2013) Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosis. Semin Nephrol 33, 375-382  https://doi.org/10.1016/j.semnephrol.2013.05.009
  8. Greer SN, Metcalf JL, Wang Y and Ohh M (2012) The updated biology of hypoxia-inducible factor. EMBO J 31, 2448-2460  https://doi.org/10.1038/emboj.2012.125
  9. Hirakawa Y, Tanaka T and Nangaku M (2017) Renal hypoxia in CKD; pathophysiology and detecting methods. Front Physiol 8, 99 
  10. Hu J, Wang W, Zhang F et al (2017) Hypoxia inducible factor-1alpha mediates the profibrotic effect of albumin in renal tubular cells. Sci Rep 7, 15878 
  11. Kong KH, Oh HJ, Lim BJ et al (2017) Selective tubular activation of hypoxia-inducible factor-2alpha has dual effects on renal fibrosis. Sci Rep 7, 11351 
  12. Deshmukh AB, Patel JK, Prajapati AR and Shah S (2012) Perspective in chronic kidney disease: targeting hypoxia-inducible factor (HIF) as potential therapeutic approach. Ren Fail 34, 521-532  https://doi.org/10.3109/0886022X.2011.653754
  13. Nangaku M, Rosenberger C, Heyman SN and Eckardt KU (2013) Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol 40, 148-157  https://doi.org/10.1111/1440-1681.12005
  14. Tanaka S, Tanaka T and Nangaku M (2014) Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol 307, F1187-F1195  https://doi.org/10.1152/ajprenal.00425.2014
  15. Tani T, Orimo H, Shimizu A and Tsuruoka S (2017) Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. Sci Rep 7, 2233 
  16. Mayer G (2011) Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 26, 1132-1137  https://doi.org/10.1093/ndt/gfq832
  17. Park JH, Jun JH, Shim JK, Shin EJ, Shin E and Kwak YL (2018) Effects of post ischemia-reperfusion treatment with trimetazidine on renal injury in rats: insights on delayed renal fibrosis progression. Oxid Med Cell Longev 2018, 1072805 
  18. Nangaku M and Eckardt KU (2007) Hypoxia and the HIF system in kidney disease. J Mol Med (Berl) 85, 1325-1330  https://doi.org/10.1007/s00109-007-0278-y
  19. Jia T, Olauson H, Lindberg K et al (2013) A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol 14, 116 
  20. Kim WY, Safran M, Buckley MR et al (2006) Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J 25, 4650-4662  https://doi.org/10.1038/sj.emboj.7601300
  21. Sulikowska B, Rutkowski B, Marszalek A and Manitius J (2015) The role of interstitial changes in the progression of chronic kidney disease. Postepy Hig Med Dosw (Online) 69, 830-837  https://doi.org/10.5604/17322693.1162570
  22. Luo F, Shi J, Shi Q, He X and Xia Y (2017) ERK and p38 upregulation versus Bcl-6 downregulation in rat kidney epithelial cells exposed to prolonged hypoxia. Cell Transplant 26, 1441-1451 https://doi.org/10.1177/0963689717720296